"White Horse Shares Business Card" Company's full name: Kangmei Pharmaceutical Co., Ltd. Registered address: Kangmei Chinese Medicine City, Jieshen Road, Puning City, Guangdong Province Company Abbreviation: Kangmei Pharmaceutical Corporate legal person: Ma Xingtian Established: 1997 Time to market: 2001-03-19 Operating income: 19.515 billion (2017Q3) Net profit: 3.151 billion (2017Q3) Total market value: 111.224 billion (2018-03-30) Starting from the trade of Chinese herbal medicines, after more than 20 years of development, Kangmei Pharmaceutical has grown into one of the leading enterprises with the most complete business chain, the most abundant resources and the strongest integration ability in the domestic Chinese medicine industry, forming a “Kangmei characteristicâ€. Integrated business model of the pharmaceutical industry chain. What nodes did Kangmei Pharmaceuticals step on, what did they do at each stage of development, and what kind of experience can they provide? The arterial network (WeChat vcbeat) is scheduled to start from the annual report and analyze the growth path of Kangmei Pharmaceutical. 5 years of growth peak The annual report data shows that after the listing of Kangmei Pharmaceutical, every five years and one cycle, it has ushered in two peaks of growth. These two growth peaks brought Kangmei Pharmaceutical to the market value of 100 billion, the revenue exceeded 20 billion, and the net profit exceeded 3 billion. The status of Chinese medicine "aircraft carrier". Kangmei Pharmaceutical's 2001-2016 revenue/revenue growth/net profit data The first growth peak of Kangmei Pharmaceutical occurred in 2006-2007. The revenue growth rate in 2006 was 41.22%, and the growth rate in 2007 was 56.74%. In 2007, revenue exceeded 1 billion yuan for the first time, just five years after its listing. Back in the past, Kangmei Pharmaceutical has completed a number of investment and preparation projects in 2003-2004, including: Commercial land in Zhanyu Town, Puning City (budget investment of 44.5 million yuan) Provincial-level Chinese Herbal Pieces Engineering Technology Research and Development Center renovation project (planned investment of 20.5 million yuan) Chinese medicine decoction piece production workshop (planned investment of 8.01 million yuan) Chinese Herbal Pieces Distribution Center (planned investment of 23.88 million yuan) Drug storage land (planned investment of 4.71 million yuan) Reserve land for chemical production base (planned investment of 4.2 million yuan) Land for the second phase of the Chinese Herbal Medicine (planned investment of 56 million yuan). The above investment projects totaled about 163 million yuan, and Kangmei Pharmaceutical was successively completed in 2003-2005. Its investment in 2003-2005 was 48.63 million yuan, 150 million yuan, and 23.08 million yuan, totaling about 222 million yuan. In addition, Kangmei Pharmaceutical promised to complete the construction project in 2001, including 4 chemical raw materials and preparation lines, totaling about 220 million yuan. The above data shows that after the listing of Kangmei Pharmaceutical, it has invested about 442 million yuan in production line construction and Chinese medicine decoction pieces workshop and storage project. After the investment was fully in place, the performance began to be realized in 2006. Therefore, it can be explained that the first wave of growth of Kangmei Pharmaceutical comes from the “Yu Yin†of the IPO. In the first round of performance growth, the fastest growth rate was the Chinese medicine decoction piece business. In 2004, Kangmei Chinese Herbal Pieces business revenue was 159 million yuan, accounting for 28.74% of the main business income; in 2005, it increased by 10.66%, and in 2006 it increased by 33.44%; in 2007, it increased by 49.23%. The income reached 350 million yuan. During the same period, other main products of Kangmei Pharmaceutical, such as Pei Ning, Luo Xinping, Kang Meinosa, and Kang Mei Li Le, also performed well. At the same time of rapid growth in performance, Kangmei Pharmaceutical opened the next round of fundraising development plans. In 2006 and 2007, Kangmei completed two additional fundraising projects: 2006 (485 million yuan) and 2007 (1.023 billion yuan), totaling about 1.5 billion yuan. In 2008, Kangmei Pharmaceutical issued a separate transaction convertible bond of 900 million yuan (also distributed 166.5 million warrants); in 2009, the warrants exercised, and raised another 890 million yuan. The above fundraising plan will raise about 3.3 billion yuan for Kangmei Pharmaceutical. These funds will be used for the China Drug Distribution Center project (planned investment of 1 billion yuan) and supplementary cash flow. Some fundraising has limited use and cannot be used. In the project construction. During this period, Kangmei’s projects include: Kangmei Hospital Project (planned investment of 600 million yuan) Kangmei Beijing Chinese Medicine Production Base (planned investment of 300 million yuan) Chengdu Chinese Herbal Pieces Production Base (planned investment of 221 million yuan) Shenzhen office building project (planned investment of 180 million yuan) Information network upgrade and e-commerce platform (planned investment of 80 million yuan) Jilin Ginseng Industrial Park Base Project (planned investment of 400 million yuan) Zhangzhou Huaying International Chinese Medicine City (planned investment of 150 million yuan) and so on. These projects were basically completed in 2010 and before, and they began to cash in on performance. Therefore, in 2011-2012, Kangmei ushered in the second round of growth peak, the revenue growth rate exceeded 83% for two consecutive years, and the revenue in 2012 exceeded 10 billion yuan. During the second round of growth of Kangmei Pharmaceutical, the rapid growth of the Chinese herbal medicine trading sector was the main driver. For example, in 2010, the trade income of Chinese herbal medicines was 1.328 billion yuan, an increase of 60% over the same period of the previous year. Accounting for more than 1/3 of total revenue, the profit margin is 44.17%, which is also higher than other business profits. Here, we conclude that the second round of growth of Kangmei Pharmaceutical comes from the continuous investment in the trade of Chinese herbal medicines/Chinese herbal medicines, and has gradually improved the construction of upstream Chinese herbal medicines, the construction of mid-stream trading platforms, and the construction of downstream logistics storage and distribution networks. It has formed a trading system and business network of Chinese herbal medicines integrating production, sales and transportation. In the same period, Kangmei Pharmaceutical completed the acquisition of 100% equity of Shanghai Meifeng Food Co., Ltd. and Shanghai Golden Elephant Food Co., Ltd. in 2009, and began to lay out food and health food. After the second round of growth, Kangmei continued to use the platform of listed companies to raise funds for development. In 2011, Kangmei completed a share placement of 3.436 billion yuan. In the same period, Kangmei issued 2.487 billion yuan of corporate bonds to repay bank loans and replenish liquidity. In the following years, Kangmei maintained a continuous investment of more than 1 billion yuan per year and continued to improve the energy storage of Chinese herbal medicine trade/Chinese herbal medicines. According to the 5-year cycle, investment will continue to be realized in 2011 and beyond. It is expected that the third-round performance growth of Kangmei will appear in 2017-2018. Six major businesses with complementary resources and complementary advantages At present, Kangmei Pharmaceutical is centered on Chinese herbal medicines and traditional Chinese medicine decoction pieces. Its business system covers the cultivation of upstream Chinese herbal medicines and resources integration; the professional market of Chinese herbal medicines in the middle reaches, Chinese herbal medicine trade, Chinese herbal medicines, Chinese patent medicine preparations, health foods, Production and sales of chemicals, modern pharmaceutical logistics systems; downstream medical institutions resources, pharmacy trusteeship, OTC retail, chain pharmacies, direct sales, pharmaceutical e-commerce, mobile medical and other integrated multi-level marketing network. Chinese Herbal Pieces: Kangmei Pharmaceutical's Chinese Herbal Pieces business is in the leading position in the industry, ranking first in terms of production and sales. The Chinese Herbal Pieces business is oriented to hospitals and has established long-term cooperative relationships with more than 2,000 medical institutions. Chinese herbal medicine trade: Since 2006, the Chinese herbal medicine trade business has been gradually developed, and it has now developed into one of the company's core businesses. In recent years, the company has continuously laid out and perfected the professional market of Chinese herbal medicines in key areas across the country, and has also established a B2B e-commerce platform for online trading of Chinese herbal medicines in the large-scale trading platform of Kangmei Chinese Herbal Medicine (Kangmei e Medicine Valley). Health food: started at the end of 2009. After the establishment of Xinkaihe Food in 2013, the company focused on promoting the food and food homogenous health food and green food business as a perfection and supplement for the big health industry, and promoted new marketing methods for e-commerce and direct sales. Currently, the sector's revenue is about 2 billion yuan. Pharmacy custody: operate and manage the hospital's pharmacy, and sell Chinese medicine decoction pieces and medicines through custody pharmacies. According to the Kangmi 2017 semi-annual report, it has more than 100 pharmacies in the nation's custody hospitals. Smart Pharmacy: Online real-time circulation and collection of patient prescriptions through the direct connection hospital HIS system, patients can also upload their own prescriptions. Under the line, the patients will be provided with traditional Chinese medicine decoction pieces and Chinese and Western medicine preparations, and Chinese medicine decoction will be delivered to the patients through the “Kangmei City Central Pharmacyâ€. The main layout is the key cities in the north, Guangzhou, and Shenzhen. Hospital operation: Self-built Kangmei Hospital, successively acquired and integrated a number of local public hospitals to achieve hospital management and management precipitation. With pharmacy hosting, supply chain extension services, "smart pharmacies", "network hospitals" and other open B and C end demand, driving Chinese herbal medicine pieces, Chinese herbal medicines trade sales.
Indoor Hydroponics Grow Kit
hydroponics system-nutrient technique (NFT)
Hydroponics is an ideal way to grow plants in urban areas. This makes it a great hobby that helps you to relax and it is fun to watch the hydroponic plants grow in the garden nft.
Indoor Hydroponics Grow Kit, Hydroponic Indoor Plant Grow Light Kit,Indoor Hydroponic Grow Tent Complete Kit JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.engreenhouse.com
NFT does not give average support to roots. Typically, the roots sit in a long sloping channel irrigation (Fig. 1.1). The nutrient is introduced into the high class of the canal and allowed to flow over the roots after which it drains into the nutrient tank. This is then re-pumped back into the channel to repeat the watering process.
This feed cycle can be intermittent or continuous. An & lsquo; The intermittent 'rss cycle is controlled by the clock and repeated several times per hour. this is sometimes called the "NFT pulse". The NFT pulse usually achieves better aeration of the roots as the roots are exposed to air between each feed. A & lsquo; continuous' rss cycle works non-stop. This is often used in commercial operations.
You can easily grow your favorite flowers at home without muddy mess and need to water your plants regularly.